Meral KAYIKCIOGLU
@meralkayikcioglu.bsky.social
📤 18
📥 39
📝 2
Honored to speak at UKRAINE & EUROPE: UNITING HEARTS, organized by Ukrainian Atherosclerosis Society. I was deeply moved to join as an online speaker to support Ukrainian Colleagues during the most difficult circumstances.
@eassociety.bsky.social
@erinmichos.bsky.social
10 months ago
2
4
2
reposted by
Meral KAYIKCIOGLU
Honored to speak at
#Riga
Lipid Conference 2025— My topic was “Homozygous FH: Clinical Approach & International Registries,” A heartfelt thank to Prof. Gustavs Latkovskis for his impeccable organization & kind hospitality. It was a pleasure to join esteemed colleagues
@eassociety.bsky.social
10 months ago
0
5
2
Honored to speak at
#Riga
Lipid Conference 2025— My topic was “Homozygous FH: Clinical Approach & International Registries,” A heartfelt thank to Prof. Gustavs Latkovskis for his impeccable organization & kind hospitality. It was a pleasure to join esteemed colleagues
@eassociety.bsky.social
10 months ago
0
5
2
reposted by
Meral KAYIKCIOGLU
Erin Michos, MD
11 months ago
Exciting!
#STRIDE
trial just presented at
#ACC25
@accintouch.bsky.social
.
#Semaglutide
improved mean walking distance, symptoms, major limb events & quality of life in patients with
#T2D
&
#PAD
. We have a new drug now to help PAD patients!
#CardioSky
1
15
11
reposted by
Meral KAYIKCIOGLU
Erin Michos, MD
11 months ago
#SOUL
trial presented at
#ACC25
. Oral
#semaglutide
reduced 3-pt major adverse cardiovascular events by 14% in patients with T2D, even with high background SGLTi use. In exploratory analysis, oral sema also reduced major limb events.
#CardioSky
@accintouch.bsky.social
1
20
14
reposted by
Meral KAYIKCIOGLU
Erin Michos, MD
11 months ago
Exciting new development in lipid field! The early Phase 2
#PURSUIT
trial showed a novel oral
#PCSK9i
(that can be taken with food) lowered LDL-C by 51% at 12 weeks. 84% achieved LDL-C of <70 mg/dL.
#ACC25
@accintouch.bsky.social
0
15
10
you reached the end!!
feeds!
log in